LGVN / laromestrocel-hlhs — Laromestrocel (Lomecel-B) for hypoplastic left heart syndrome

Program analysis · bpiq_drug_id 14275 · prepared 2026-08 · USD · framework v5.6.1 · Coverage: CLEARED

Company context, financials, ownership, options and the full pipeline: ../company.md.

How to read this. Written for a reader who has not studied pharmacology or finance. Terms specific to this program are in the Glossary below; general terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

Glossary

Executive summary

• What it is (one sentence): Donor bone-marrow stem cells injected into a baby’s overworked right ventricle during the second of HLHS’s three palliative operations, aiming to strengthen the muscle and delay failure or transplant.
• The event and when (as disclosed): ELPIS II Phase 2b topline, guided “August 2026” — this month; the Q2 report and call are 2026-08-12, the day after this analysis.
• The main reason it could work: The registered pump-function endpoint aside, the clinical signal in this exact surgical setting is real: the independent CHILD trial (different cells, same operation) saw far fewer adverse events and hospital days in cell-treated babies, and ELPIS I’s 10 babies were all alive and transplant-free years out.
• The main risk: The FDA has already told the company the trial’s registered primary endpoint (RVEF) cannot demonstrate efficacy, no replacement endpoint is agreed, and the trial has lost its “pivotal” label — so even statistically positive topline may not mean an approvable result, and at n=40 the re-powered clinical composite can easily miss.
• What it means for the stock: A ~$23M market-cap single-asset company whose financing structure literally prices the win (second tranche requires a ≥$1.85 ten-day VWAP); the probability-weighted value sits almost exactly at spot, so this is a lottery-ticket setup, not an edge.

0. Program-tier coverage — CLEARED

Company-tier coverage is in ../company.md C.0.

A. Scientific & clinical assessment

A.1 Mechanism of action and scientific rationale

Laromestrocel is an allogeneic mesenchymal stem cell (MSC) product: bone-marrow cells from screened young adult donors, culture-expanded, cryopreserved, and — in this program — thawed and injected at multiple sites directly into the right ventricular muscle while the chest is already open for the Glenn operation [VERIFIED — ELPIS I publication, DOI 10.1093/ehjopen/oead002; CT.gov NCT04925024].

The scientific idea is not that the donor cells become new heart muscle. MSCs are short-lived after transplantation; the working model is paracrine: the cells secrete anti-inflammatory cytokines, pro-vascular growth factors and exosomes that reduce inflammation, promote small-vessel growth and favourably remodel the pressure-overloaded ventricle. The ELPIS I exosome analysis identified MSC-derived RNA cargo (miR-215-3p, miR-374b-3p, MAPK-pathway RNAs) whose levels tracked improvement in tricuspid regurgitation [VERIFIED — DOI 10.1093/ehjopen/oead002]. The same mechanism story — immunomodulation rather than engraftment — underpins the company’s positive published trials of the identical cells in Alzheimer’s disease (Nature Medicine 2025, DOI 10.1038/s41591-025-03559-0) and aging frailty (Cell Stem Cell 2026, DOI 10.1016/j.stem.2026.01.017) [VERIFIED — PubMed].

What the next readout must prove: that this biological help is large enough to move hard clinical measures — survival, transplant, adverse cardiac events, hospital days — in 20 treated babies against 20 controls within 12 months. The honest scientific risk: every controlled attempt to show cell therapy moves imaging measures of RV function in this population has failed, including the CHILD trial’s primary endpoint (DOI 10.1016/j.jchf.2025.102723) and the Mayo Clinic’s cord-blood Phase 2b, whose clinical findings were unfavourable (letter, DOI 10.1186/s13287-025-04717-4). The field’s own reviewers argue the delivery mode and timing may not match the growing infant myocardium (same letter). The claim that MSC paracrine signalling can alter the clinical course of a surgically palliated single-ventricle heart remains unproven in any powered trial [VERIFIED — the cited record; the interpretation is the analyst's].

A.2 Clinical development plan, timeline, feasibility, resourcing

Trials

[VERIFIED — CT.gov and the cited PubMed records, read 2026-08-11]

Timeline detail (ELPIS II): start 2021-06-25 · first patient about mid-2021 · last patient in 2025-06-24 (enrollment ran ~4 years for 40 babies — this is a hard population to enrol) · last 12-month assessment / registry primary completion 2026-06-30 · registry study completion 2026-08-31 · topline guided August 2026 [VERIFIED — CT.gov; company guidance via BPIQ note and Q1 2026 call].

Feasibility matrix

Resourcing sufficiency. Cash covers the readout ($15.8M at 2026-03-31, runway into Q4 2026) but not what follows: BLA-enabling work is ramping, the ATM is blocked below $0.80 until 2026-09-07, and the $15M second tranche only arrives on a statistically significant win plus a ≥$1.85 VWAP (or investor waiver). A confirmatory trial, if the FDA demands one, is unfunded. See ../company.md C.3 [VERIFIED — Q1 2026 10-Q].

A.3 Target label, target product profile, strategic questions, designations

A.3a Target label. Adjunct to stage-2 (Glenn) surgical palliation in infants with hypoplastic left heart syndrome: a single intramyocardial administration of allogeneic bone-marrow MSCs during the operation.

A.3b Target product profile

A.3c Strategic Go/No-Go questions (pre-Phase-III / registration set — this readout decides whether a registration case exists)

A.3d Regulatory designations (all five held on this program’s drug) [VERIFIED — Q1 2026 call; AAIC release 2026-07-13 confirms RMAT and Fast Track wording]

• RMAT — earlier, more frequent FDA interactions and potential eligibility for accelerated pathways for a regenerative therapy.
• Fast Track (HLHS, granted 2022) — rolling review eligibility and more FDA contact.
• Orphan Drug (HLHS) — 7 years of US market exclusivity on approval, fee waivers, tax credits.
• Rare Pediatric Disease designation — eligibility for a Priority Review Voucher on approval; the PRV program was reauthorised through September 2029 in the 2026 appropriations act, so the eligibility is live again; 50% of any voucher proceeds are already sold (see ../company.md C.3).
• EMA SME status (2026-06-09) — fee reductions for EU procedures; administrative, not evidential.

A.4 Target product profile valuation matrix

A.5 Evidence quality and endpoints

Endpoints

A.5b Key opinion leaders.

Panel as of. 2026-08-11 — CT.gov search_investigators (returned no ELPIS II investigators: the registry lists no overall official and no site contacts on any of the 10 locations) and PubMed author searches run this day.

Investigators

ELPIS II’s own site investigators are not disclosed on CT.gov (every contact field null); the trial’s named collaborators are NHLBI, Lurie Children’s and UT Houston’s biostatistics center. The panel above is built from the program’s publications instead, with each name’s verifiable trial attachment stated.

Independent voices

Judgement

Dissent

(empty — the judgement is MIXED, not SUPPORTIVE_CONTESTED, so no named dissent from a majority reading is required; the Brizard/Pepe caution is already recorded above.)

B. Commercial assessment

B.0 Current treatment algorithm

1. Prenatal or newborn diagnosis by echocardiography; prostaglandin keeps the ductus open.
2. Stage 1 — Norwood operation, days after birth: the RV becomes the systemic pump. Highest-risk period; interstage mortality remains meaningful.
3. Stage 2 — Glenn operation, 4–6 months: superior vena cava routed to the lungs. This is where laromestrocel is given, during the operation already happening — it opens no new line of therapy and adds no separate procedure.
4. Stage 3 — Fontan, 2–4 years: full venous rerouting. The child lives with single-ventricle physiology; late RV failure, protein-losing enteropathy and transplant need accumulate for life.
5. Heart transplant is the only option when the RV fails — scarce infant donor hearts, lifelong immunosuppression.

There is no approved drug therapy for HLHS at any step; everything pharmacological is supportive [VERIFIED — web sweep; FDA's Type C framing per Q1 call]. If approved, laromestrocel would slot inside step 3 as an adjunct for essentially every Glenn candidate — the addressable population is the treated population.

B.1 Competitive landscape and positioning

Where this asset wins, in plain sentences. It is the only company-sponsored therapeutic anywhere in HLHS, in a population every payer and regulator agrees is desperate, with an off-the-shelf product given during an operation that happens anyway. The single fact the thesis rests on: whether 20-vs-20 babies can show a statistically significant clinical difference at 12 months. The CHILD trial says the event rates in this population are high enough that it is possible; the Mayo readout and the CHILD imaging miss say most ways of measuring it fail.

B.2 Addressable market

The company states an HLHS market opportunity of “approximately $1 billion” [VERIFIED that they say it — Q1 2026 call; the figure itself UNVERIFIED and not used].

B.3 Value and feasibility

B.3a Expected peak sales. Bottom-up, conditional on approval, excluding AD/PDCM/frailty and any PRV proceeds. Named price anchor: Ryoncil, the first approved allogeneic bone-marrow MSC therapy, at $194K per infusion [WEB ESTIMATE — BioSpace, read 2026-08-11]; laromestrocel here is a single intra-operative administration.

B.3b Feasibility

B.4 Product-development risk

Framing questions.

1. Does the development plan support the target product profile claims? Only partially — the TPP now rests on clinical-outcome claims the trial was not originally powered for, under an SAP the FDA has not yet accepted.
2. Will the identified risks affect the TPP? Yes, directly: if only RVEF or soft secondaries move, there is no approvable claim at all.
3. If a risk cannot be mitigated, is the asset still differentiated? Yes — sole company-sponsored entrant in the indication; but differentiation without an approvable endpoint is worth little.

Readout

Sources

The modelled estimate. Last 12-month assessments completed by 2026-06-30 (registry); default lag of 2–4 months to database lock, unblinding, event adjudication and topline analysis puts the modelled announcement at 2026-08-30 to 2026-10-31. The company is guiding to the earliest slice of that range and has held the month across two quarters.

Window

Basis. Earliest is the scheduled Q2 call (2026-08-12), the first dated venue inside the guided month, one day after this analysis. Likeliest is late August: inside the guided “August 2026”, allowing for the SAP submission and event adjudication still running in May. Latest is end-October: the modelled default-lag tail — a sponsor announcing its first pivotal-scale readout under a not-yet-accepted SAP can plausibly slip past its guided month by some weeks, and the modelled range extends there.

Disagreement. CONSISTENT — bpiq and company are the same statement; the ctgov date plus the default lag brackets the guided month rather than contradicting it.

Date slippage.

Zero slips: Q3 2026 → August 2026 is a narrowing inside the same quarter, never a push.

Attribution

Computed by lib/clustering.mjs attributionFor('LGVN', …, 14275) over every pipeline row, 2026-08-11 — transcribed below.

Status. CLEAN

Conflicts

(empty — exactly as computed: the other four pipeline rows all carry has_catalyst: false.)

Note. (blank — status is CLEAN.)

Market and timing for this event

• Plain takeaway. A ~$23M market-cap company with no options market, thin trading, a financing structure that pays out only on a win, and a readout window that opens tomorrow. Everything is this one event; there is no run-up left to trade, only the binary.
• Months to this catalyst. 0.0 to readout.window.earliest (2026-08-12) — the window opens the day after this analysis; 2.7 months to the latest edge (2026-10-31).
• Expected move around this event. Not computable from options and not bracketable: no listed chain exists at all (../company.md C.6). The scenario table below is the only quantification offered.
• Nearest comparable past reaction. None is truly comparable — Longeveron has never reported a controlled efficacy readout. The closest analogues in ../company.md C.7 are 2025-06-24 (+13.8% on the ELPIS II clock starting) and 2025-07-08 (+27.2% on the PDCM IND); the +68% close-to-close of 2026-03-10 was financing relief, not data.
• Materiality. Dominant, per ../company.md C.2 — the only has_catalyst row, the contractual trigger of the second tranche and the PRV interest, and the only kind of news the tape has paid for all year. The stock call below is sized to that dominance.
• Date slippage. Zero slips (Readout, above) — guidance has only ever narrowed.

Spot. $0.74, read 2026-08-11 (BPIQ; committed cache close $0.736 on 2026-08-10), per ../company.md C.4.

Scenario prices

Expected value. 0.30 × $1.70 (positive midpoint) + 0.70 × $0.335 (miss midpoint) = $0.74, +0.6% against spot $0.74. Method: probability_pct applied to the midpoint of each scenario range. This is arithmetic, not advice, and it is not a price target.

Run-up

Entry and exit

T-1 is the only admissible rule that resolves at or after entry: T-5 and T-2 would resolve before the lock date and pre-register a trade that cannot be taken. resolveExit("T-1", …) returns null at lock (the committed cache ends 2026-08-10, before the window opens), so exit is null until settlement, as the schema anticipates.

Predicted move and peak

Priority score drivers

Five computed rows transcribe lib/runup.mjs scoreDriver output verbatim; the two judgement rows are the analyst’s, with their reading stated.

Priority score 28 · formula_version 1.0.0

Settlement. Left null at lock time, per 05-prediction-protocol.md.

Verdict

What I would do. Watch. Do not initiate before the readout.

Why. The expected value sits within a rounding error of spot: a 30% shot at roughly tripling against a 70% chance of losing half to two-thirds. That is a fair lottery ticket, not an edge, and three structural facts argue against paying for it blind. First, the FDA has already told the company its registered primary endpoint cannot show efficacy and has withdrawn the trial’s pivotal label, so even a statistically positive announcement starts a regulatory argument rather than ending one. Second, the readout window opens tomorrow — there is no run-up left to harvest, only the binary. Third, the capital structure meters the upside: 22.8M preferred shares convert at $0.52, 13.2M warrants supply stock at $0.85, and the second tranche prints $15M of new equity precisely when the stock sustains $1.85 — every rally into the win scenario meets contractual sellers and issuance. What makes this genuinely interesting rather than dismissible is the CHILD precedent: in this exact operation, clinical-event endpoints separated cell-treated babies from controls at half this trial’s size, and those are the endpoints the FDA now says matter and the SAP is being rebuilt around.

What would change this. Upward, before the event: FDA acceptance of the revised SAP disclosed publicly (it would restore a scoreable, agreed definition of success and materially raise the approval-conditional value); or topline slipping past August with the ATM unlocking above $0.80 — a financing tell. Upward, at the event: statistical significance on mortality/transplant-free survival specifically, the one result that forces the FDA’s hand. Downward: both blinded on-trial deaths landing in the treatment arm — at 20 per arm that ends the program regardless of the other numbers.

What to watch.

• 2026-08-12 — Q2 2026 results call (scheduled 2026-08-03): topline itself, or the last dated guidance restatement before it; any SAP-status disclosure; the cash figure against the modelled ~$11.3M.
• Through 2026-09-07 — whether the stock holds above $0.80, the contractual level at which the $10.7M ATM unlocks early; usage would appear in an 8-K/prospectus supplement.
• Any day — the topline 8-K/press release: read the endpoint claimed (SAP composite vs registered RVEF), the p-value discipline, and the arm allocation of the two disclosed deaths.
• Within 30 trading days after a positive announcement — the 10-day ≥$1.85 VWAP / 25M-share volume test that triggers (or fails to trigger) the $15M second closing; a waiver announcement instead would itself be informative about investor conviction.
• 2026-10-31 — the latest edge of the modelled window; passing it without topline breaks the zero-slip record and reopens the timing question.

Locked prediction

• Outcome-direction (will the readout succeed on its primary endpoint?): miss — probability 30%, band 20–40% [UNVERIFIED — modelled] — the probability that the settlement definition below is met. Reasoning: controlled cell-therapy trials in this field have never hit an imaging primary (CHILD missed; Mayo unfavourable), the SAP composite is being re-specified mid-stream and is not FDA-agreed, and n=20/arm gives little power against adjudication noise — against that, CHILD’s clinical-event separation at n=8:8 in this same operation and ELPIS I’s 100% transplant-free survival say the effect, if real, is large enough to show. No published third-party probability on this event was found.
• Stock-direction (which way do the shares move?): no-edge — confidence low — window 2026-08-11 to 2026-11-14, basis: the readout window (earliest 2026-08-12, latest 2026-10-31) plus two weeks of post-announcement settlement; materiality dominant per ../company.md C.2, so the move in this window belongs to this program alone (attribution CLEAN). The no-edge call agrees with the expected value sitting +0.6% from spot.
• Scenario prices: positive $1.20–$2.20 · miss $0.22–$0.45 (anchors in the table above)
• Expected value: $0.74, +0.6% against spot $0.74 (arithmetic, not advice)
• Run-up: entry $0.74 on 2026-08-11, exit rule T-1 trading days before readout.window.earliest — predicted move −5% to +12%, predicted peak 0% to +20% around 2026-08 — priority score 28, formula_version 1.0.0
• Settles on: Longeveron’s topline announcement of ELPIS II (NCT04925024). Positive = the announcement reports a statistically significant (p<0.05) benefit of laromestrocel over the standard-of-care control arm on the trial’s primary efficacy endpoint as pre-specified in the statistical analysis plan in force at announcement — the registered primary is change in RVEF from baseline to 12 months; the company has stated the SAP it is submitting to the FDA is built on clinical measures (mortality, transplant-free survival, MACE, hospitalisation days). An announcement claiming only numerical trends, only secondary or biomarker wins, or “clinically meaningful” results without statistical significance on the declared primary settles as a miss. Primary source: the company’s topline press release / Form 8-K.
• Locked: yes · Settled: no

Program data-quality flags

• Open Targets BLOCKED across three attempts this sweep, verbatim Rate limit exceeded for client: global — the standing platform block. No independent target-validation read exists; for a multi-mechanism cell therapy the cost is low, but the absence is recorded rather than papered over.
• ChEMBL has no record of a cell therapy: two searches returned zero compounds. Molecular identity and off-target profile are not establishable from ChEMBL for this asset class.
• The trial’s registered primary endpoint and its approvable endpoint have diverged. CT.gov still shows ΔRVEF at 12 months as primary; the FDA has ruled it uninformative and the company is submitting a revised SAP. The settlement definition names both, but which endpoint the topline release leads with is itself unknowable in advance — flagged as the central interpretive risk of scoring this prediction.
• Two on-trial deaths are disclosed but blinded (one pre-Glenn, one post-Glenn, per the Q1 call). Their arm allocation flips the safety story entirely and cannot be known before topline.
• CT.gov discloses no investigators for NCT04925024 — no overall official, no site contacts. The KOL investigator panel is built from the program’s publications instead.
• The COI statements of the ELPIS I and CHILD papers were not retrieved this sweep (metadata only); sponsor co-authorship is read from author affiliation lists, which understates consultancy-type conflicts. Recorded in conflicts_checked as a limit.
• BPIQ’s catalyst_date 2026-08-31 is the month-end placeholder for “August 2026” (rule 23) — used nowhere for timing; every timing decision reads the Readout window above.
• Analyst aggregator targets conflict wildly (MarketBeat consensus $10.20 from 5 analysts vs a $1.36 average “forecast” on StockScan; WallStreetZen shows no target). The figures look stale and/or split-distorted; they are excluded from the scenario anchors on rule 6 rather than passed through.